2,5-Difluoroaniline

We are 2,5-Difluoroaniline CAS:367-30-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,5-Difluoroaniline
CAS.NO:367-30-6
Synonyms:2,5-Difluoroaniline
Molecular Formula:C6H5F2N
Molecular Weight:129.10700
 
Physical and Chemical Properties:
Density:1.288
Melting point:11-13ºC
Boiling point:176-178ºC
Flash point:156°F
Index of Refraction:1.513
 
Specification:
Appearance:Yellow-brown liquid
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

2,5-Difluoroaniline


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.27475-09-8 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.1558-25-4 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.1-[2-amino-6-[(2,2,2-trifluoroacetyl)amino]hexanoyl]pyrrolidine-2-carboxylic acid From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
Pentagastrin View Details
6-Chloro-5-fluoroindole View Details
2′-broMo-2,7-di-tert-butyl-9,9′-spirobi[fluorene] View Details
2-Bromo-5-(trifluoromethyl)pyridine manufacturer 3-Cyano-4-(2-methylpropoxy)benzenecarbothioamide manufacturer 3-Nitro-5-(trifluoromethyl)-2-pyridinol manufacturer Glyoxylic Acid manufacturer 3-Bromo-4-fluorobenzaldehyde manufacturer